| 產(chǎn)品名稱 | TMP 195 - TFMO 2 |
| 產(chǎn)品貨號 | Axon 2180 CAS [1314891-22-9] MF C23H19F3N4O3MW 456.42 Purity: 99% Soluble in DMSO Description Selective and cell-active class IIa histone deacetylase (HDAC) inhibitor, with IC50 values of 111, 106, 46, 9 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively; >100 fold more selective vs other HDACs (IC50: >10 μM).The trifluoromethyloxadiazole (TFMO) moiety in TMP 195 as a new metal binding group circumvents the selectivity and pharmacologic liabilities of hydroxamates groups used in other metalloenzyme inhibitors. TMP 195 has a restraint impact on gene expression, and lacks overt cytotoxicity. KEYWORDS: TMP 195 | supplier | IIa HDAC inhibitor | TFMO 2 | TMP195 | TFMO2 | TMP-195 | TFMO-2 | CAS [1314891-22-9] | Histone | Deacetylase | HDAC | Inhibitor | Enzymes |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
TMP 195 - TFMO 2Axon 2180 CAS [1314891-22-9] MF C23H19F3N4O3
DescriptionSelective and cell-active class IIa histone deacetylase (HDAC) inhibitor, with IC50 values of 111, 106, 46, 9 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively; >100 fold more selective vs other HDACs (IC50: >10 μM).The trifluoromethyloxadiazole (TFMO) moiety in TMP 195 as a new metal binding group circumvents the selectivity and pharmacologic liabilities of hydroxamates groups used in other metalloenzyme inhibitors. TMP 195 has a restraint impact on gene expression, and lacks overt cytotoxicity. KEYWORDS: TMP 195 | supplier | IIa HDAC inhibitor | TFMO 2 | TMP195 | TFMO2 | TMP-195 | TFMO-2 | CAS [1314891-22-9] | Histone | Deacetylase | HDAC | Inhibitor | Enzymes
HDAC inhibitor (class IIA selective)
Chemical nameN-(2-methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide Parent CAS No.[1314891-22-9] |
| 產(chǎn)品資料 |
